Search Results
Apr 15, 2026, 08:00 ET Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform
Kazia. PI3K/mTOR is a key driver of tumour growth and a master regulator of epigenetic programs that shape tumour behaviour, the tumour microenvironment (TME), and immune evasion," stated Dr. Rao. "We are building a platform focused on precision targeting and precision medicine, integrating spatial and liquid
More news about: Kazia Therapeutics Limited
Apr 14, 2026, 06:00 ET Tencent Music Entertainment Group to Report First Quarter 2026 Financial Results on May 12, 2026
SHENZHEN, China, April 14, 2026 /PRNewswire/ -- Tencent Music Entertainment Group ("TME", or the "Company") (NYSE: TME and HKEX: 1698), the leading online music and audio entertainment platform in China, today announced that it will report its unaudited
More news about: Tencent Music Entertainment Group
Apr 13, 2026, 18:12 ET Agillence and Toyota Motor Europe Enter Long-Term Contract for Inbound Logistics Optimization
provider of advanced supply chain optimization software, today announced it has entered into a long-term contract with Toyota Motor Europe N.V./S.A. (TME) to continue providing its proprietary
More news about: Agillence, Inc
Apr 13, 2026, 00:00 ET AnBogen Therapeutics to Present Dual Breakthroughs for Imofinostat (ABT-301) at AACR 2026: Addressing Immunotherapy Barriers in CRC and Chemo-resistance in Pancreatic Cancer
15)Key Breakthrough: Preclinical data confirms that Imofinostat, acting as an HDAC inhibitor, effectively modulates the tumor microenvironment (TME). By synergizing with immune checkpoint inhibitors and anti-angiogenic agents, it converts "cold tumors" into "hot tumors," significantly enhancing the
More news about: Anbogen Therapeutics
Apr 13, 2026, 00:00 ET AnBogen Therapeutics to Present Dual Breakthroughs for Imofinostat (ABT-301) at AACR 2026: Addressing Immunotherapy Barriers in CRC and Chemo-resistance in Pancreatic Cancer
15)Key Breakthrough: Preclinical data confirms that Imofinostat, acting as an HDAC inhibitor, effectively modulates the tumor microenvironment (TME). By synergizing with immune checkpoint inhibitors and anti-angiogenic agents, it converts "cold tumors" into "hot tumors," significantly enhancing the
More news about: Anbogen Therapeutics
Apr 08, 2026, 05:50 ET Portrai to Present 11 Posters on AI-Driven Spatial Transcriptomics at AACR 2026
2026. The presentations will detail Portrai's latest computational frameworks and biological findings, designed to decode the tumor microenvironment (TME) and accelerate oncology drug development.
More news about: Portrai, Inc.
Mar 28, 2026, 00:54 ET Sales of Jay Chou's "Children of the Sun" have exceeded 100 million RMB, as Tencent Music Entertainment Group Drives Global Rollout
eeded-100-million-rmb-as-tencent-music-entertainment-group-drives-global-rollout-302727861.htmlSOURCE Tencent Music Entertainment Group (TME)
More news about: Tencent Music Entertainment Group (TME)
Mar 26, 2026, 09:08 ET Vanguard Launches Target Maturity Corporate Bond ETF Suite
and cost-conscious wrapper."Each ETF in the suite has an expense ratio of 0.08%,1 making Vanguard BondBuilder™ suite the lowest cost TME ETFs on the market.2 The funds are designed to help investors manage interest rate risk and credit risk while simplifying portfolio construction
More news about: Vanguard
Mar 26, 2026, 08:53 ET CStone Updated Clinical Progress and Key Phase I/II Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)
activity promotes T cell activation and proliferation, while anti-VEGFA activity blocks tumor angiogenesis and improves the tumor micro-environment (TME). In the TME, anti-PD-1 and anti-CTLA-4 activities are significantly enhanced by crosslinking with VEGFA. Meanwhile, CS2009 preferentially blocks PD-1 and
More news about: CStone Pharmaceuticals
Mar 18, 2026, 07:44 ET Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026
JZP898, a conditionally activated interferon alpha, generates efficacy and robust TME engagement in syngeneic mouse modelsKarmokar
More news about: Jazz Pharmaceuticals plc
Mar 17, 2026, 05:00 ET Tencent Music Entertainment Group Announces Fourth Quarter and Full-Year 2025 Unaudited Financial Results
SHENZHEN, China, March 17, 2026 /PRNewswire/ -- Tencent Music Entertainment Group ("TME," or the "Company") (NYSE: TME and HKEX: 1698), the leading online music and audio entertainment platform in China, today announced its unaudited financial results
More news about: Tencent Music Entertainment Group
Mar 05, 2026, 07:56 ET GNTbm's self-developed anti-cancer new drug GNTbm-38 has obtained IND approval from the U.S. FDA for Phase I clinical trials
remodel the tumor microenvironment (TME) through a unique epigenetic regulatory mechanism, primarily affecting the cellular composition and gene expression of the TME, turning originally "cold tumors" into "hot tumors," thereby attracting more CTL infiltration into the TME. At the same time, it can also reduce
More news about: Great Novel Therapeutics Biotech & Medicals Corporation
Mar 03, 2026, 02:51 ET Senhwa Biosciences Signs Major Strategic MOU with Y Combinator-Backed AI Biotech Company CellType to Accelerate the Evolution of CX-4945 into Version 2.0 and Reshape the Global Immunotherapy Landscape
applies large language models to single-cell gene expression—the first of its kind—enabling sophisticated decoding of complex tumor microenvironment (TME) signaling.Through the original research collaboration with Google DeepMind at Yale University, researchers screened over 4,000 compounds and
More news about: Senhwa Biosciences, Inc.
Feb 15, 2026, 19:10 ET CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 (PD-1/VEGF/CTLA-4) to Advance into Phase II Clinical Trial
activity promotes T cell activation and proliferation, while anti-VEGFA activity blocks tumor angiogenesis and improves the tumor micro-environment (TME). In the TME, anti-PD-1 and anti-CTLA-4 activities are significantly enhanced by crosslinking with VEGFA. Meanwhile, CS2009 preferentially blocks PD-1 and
More news about: CStone Pharmaceuticals
Feb 11, 2026, 20:00 ET 300개 이상의 아시아 기업, 알리멘타리아+호스텔코 2026 참가
식물성 오일 등 분야에서 강한 존재감을 보이고 있다. 중국은 알리멘타리아+호스텔코에서 이탈리아와 폴란드에 이어 세 번째로 큰 해외 참가국으로서의 입지를 더욱 공고히 했다. 이번 박람회에 참가하는 아시아 주요 기업들에는 아시아의 비드푸드(BidFood), 말레이시아의 TME, 인도의 빅 바스켓(Big Basket), 대한민국의 롯데마트(Lotte Mart) 체인 등이 있다.
More news about: Fira de Barcelona
Feb 10, 2026, 21:00 ET More than 300 Asian companies will participate in Alimentaria + Hostelco 2026
exhibiting country at Alimentaria + Hostelco, only behind Italy and Poland. Among the leading Asian companies present at the show are BidFood (Asia), TME (Malaysia), Big Basket (India) and the Lotter Mart chain (South Korea), among others.
More news about: Fira de Barcelona
Feb 10, 2026, 05:00 ET Tencent Music Entertainment Group to Report Fourth Quarter and Full Year 2025 Financial Results on March 17, 2026
SHENZHEN, China, Feb. 10, 2026 /PRNewswire/ -- Tencent Music Entertainment Group ("TME", or the "Company") (NYSE: TME and HKEX: 1698), the leading online music and audio entertainment platform in China, today announced that it will report its unaudited
More news about: Tencent Music Entertainment Group
Feb 06, 2026, 06:20 ET NITECORE nastavuje nový štandard pre ultraľahký výkon: nový NB10000 Gen4 s hmotnosťou 143 g a krytím IPX7
napájané aj na cestách. Pre rýchle nabíjanie poskytuje bežný režim rýchle zapnutie, kedykoľvek ho potrebujete.Bezproblémová prevádzka v tmeFunkcia Knock-to-Wake zvyšuje použiteľnosť v podmienkach so slabým osvetlením, a to aj v rukaviciach, zatiaľ čo intuitívne dynamické RGB polohovacie
More news about: NITECORE
Feb 06, 2026, 06:13 ET NITECORE stanovuje nový standard pro ultralehké napájení: nový model NB10000 Gen4 o hmotnosti 143 g s krytím IPX7
vydrží déle v provozu i na cestách. Pro rychlé nabíjení poskytuje režim Regular rychlé nabití, kdykoli to potřebujete.Snadné ovládání ve tměFunkce „ťukni, abys probudil" zvyšuje použitelnost za zhoršených světelných podmínek, a to i při nošení rukavic, zatímco intuitivní dynamická
More news about: NITECORE
Feb 05, 2026, 04:09 ET HanchorBio Accelerates Global Clinical Footprint with Multiple Oral and Poster Presentations in Q1 2026
first-in-class multi-specific candidate targeting the CD47/SIRPα, PD-1/PD-L1, and TGFb pathways to overcome the immunosuppressive tumor microenvironment (TME)."The concentration of oral and poster presentations at premier global forums like AACR-IO and ESMO-TAT reflects the significant momentum
More news about: HanchorBio Inc.
Jan 22, 2026, 05:31 ET 東西方思想交匯與文明互鑑的「國際文化會」香港「中華聖經文物館」 結合千年信仰與當代安全教育「生命方舟」開幕
https://www.prnewswire.com/apac/zh/news-releases/--302667984.htmlSOURCE The Media Evangelism Limited ("TME")
More news about: The Media Evangelism Limited ("TME")
Jan 20, 2026, 06:20 ET 從現實「安全」到信仰「平安」的跨越之路 香港「中華聖經文物館」 結合千年信仰與當代安全教育「生命方舟」率先開放傳媒預覽
https://www.prnewswire.com/apac/zh/news-releases/---302665305.htmlSOURCE The Media Evangelism Limited ("TME")
More news about: The Media Evangelism Limited ("TME")
Jan 16, 2026, 08:00 ET Henlius Showcases "Globalisation 2.0" Strategy and Mid-to-Long-Term Innovation Blueprint at JPM 2026
developed based on the immune checkpoint inhibitor platform. It demonstrates high PD-L1 binding affinity and achieves higher tumour microenvironment (TME) enrichment vs. combination therapies, positioning it as a next-generation immunotherapy candidate following serplulimab.HLX97: Novel
More news about: Henlius
Jan 13, 2026, 09:13 ET Aignostics stellt ein neues, hochmodernes Pathologie-Grundlagenmodell vor
Produktportfolio einsetzen, einschließlich Atlas H&E-TME, seiner Anwendung für die Erstellung von Profilen der Mikroumgebung von Tumoren in H&E-Objektträgern. Atlas 2 wird auch zur Lizenzierung
More news about: Aignostics
Jan 13, 2026, 09:00 ET Aignostics Announces New State-of-the-Art Pathology Foundation Model
Atlas H&E-TME, its application for tumor microenvironment profiling in H&E slides. Atlas 2 will also be available for licensing."Atlas 2 demonstrates
More news about: Aignostics